Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.31 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.30 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9976319 | 0.94 | LMNA (0.43) | LMNACYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL13220206 | 0.93 | LMNA (0.50) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL10044863 | 0.91 | LMNA (0.45) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL13247497 | 0.90 | LMNA (0.48) | LMNACYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL13247513 | 0.89 | LMNA (0.47) | LMNACYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL3047186 | 0.88 | LMNA (0.45) | LMNACYP2C19HIF1A | |
| SCHEMBL13247485 | 0.88 | LMNA (0.50) | LMNACYP2C19HIF1ASMN1; SMN2MAP2K1 | |
| SCHEMBL13247598 | 0.87 | LMNA (0.48) | LMNACYP2C19HIF1A | |
| SCHEMBL3067900 | 0.87 | LMNA (0.47) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL7593885 | 0.86 | LMNA (0.44) | LMNACYP2C19HIF1ASMN1; SMN2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100221189-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | claimed |
| EP-2200656-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-06-30 | — | — | EP | claimed |
| WO-2009047319-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-04-16 | — | — | WO | claimed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221189-A1 | CONTRAST AGENTS | NR1I3, NR1I2, NR1D2 | LMNA 2753/4885CYP2C19 754/4885HIF1A 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.